ALE1

Small molecule

AAlesta Therapeutics

ALE1 is one of 11 small molecule programs targeting Hypophosphatasia. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypophosphatasiaActive, not recruiting

HypophosphatasiaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Hypophosphatasia

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Approved

1 2

Rituxan

Roche

Approved

1 3

Folvite

Eli Lilly

Approved

1 4

Fosrenol

Takeda

Approved

—5

Velcade

SShilpa Grover, MD, MPH

Approved

1 6

Ivig

Argenx

Approved

1 7

STRENSIQ

AstraZeneca

Phase 2

14 8

ALXN1850

AstraZeneca

Phase 3

2 9

BPS804

Ultragenyx

Phase 2

1 10

Ilofotase Alfa

AAM-Pharma

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Hypophosphatasia

NCT07179640

Clinical

Trials by Indication[1]

Hypophosphatasia1 trial

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1

Recruiting·AAlesta Therapeutics·Phase 1/2·NCT07179640·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ALE1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALE1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALE1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alesta Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: AAlesta Therapeutics

ALE1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Hypophosphatasia1 trial

References

Drug Info

Quick Facts

Related News